2. Academic Validation
  3. Synthesis and evaluation of 2-{[2-(4-hydroxyphenyl)-ethyl]amino}pyrimidine-5-carboxamide derivatives as novel STAT6 inhibitors

Synthesis and evaluation of 2-{[2-(4-hydroxyphenyl)-ethyl]amino}pyrimidine-5-carboxamide derivatives as novel STAT6 inhibitors

  • Bioorg Med Chem. 2007 Jan 15;15(2):1044-55. doi: 10.1016/j.bmc.2006.10.015.
Shinya Nagashima 1,  Masaki Yokota,  Ei-Ichi Nakai,  Sadao Kuromitsu,  Keiko Ohga,  Makoto Takeuchi,  Shin-Ichi Tsukamoto,  Mitsuaki Ohta
Affiliations

Affiliation

  • 1 Institute for Drug Discovery Research, Astellas Pharm Inc., 2-1-6, Kashima, Yodogawa-ku, Osaka 532-8514, Japan. [email protected]
PMID: 17071093 DOI: 10.1016/j.bmc.2006.10.015
Abstract

The STAT6 (signal transducers and activators of transcription 6) protein is activated by interleukin (IL)-4 and IL-13, and plays an important role in T-helper cell 2 (Th2) differentiation. STAT6 might therefore be an excellent therapeutic target for various allergic conditions, including asthma and atopic diseases. We synthesized a series of 2-{[2-(4-hydroxyphenyl)ethyl]amino}pyrimidine-5-carboxamide derivatives and evaluated their STAT6 inhibitory activities. Among these compounds, 4-(benzylamino)-2-{[2-(3-chloro-4-hydroxyphenyl)ethyl]amino}pyrimidine-5-carboxamide (2t, AS1517499) showed potent STAT6 inhibition with an IC(50) value of 21 nM, and also inhibited IL-4-induced Th2 differentiation of mouse spleen T cells with an IC(50) value of 2.3 nM and without influencing T-helper cell 1 (Th1) differentiation induced by IL-12.

Figures
Products